Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics.

Huemer, F; Rinnerthaler, G; Lang, D; Hackl, H; Lamprecht, B; Greil, R; Ann Oncol. 2019; 30(4): 652-653.

Cytotoxic Properties of Damiana (

Willer, J; Johrer, K; Greil, R; Zidorn, C; Cicek, SS MOLECULES. 2019; 24(5):

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with

Schlenk, RF; Weber, D; Fiedler, W; Salih, HR; Wulf, G; Salwender, H; Schroeder, T; Kindler, T; Lübbert, M; Wolf, D; Westermann, J; Kraemer, D; Götze, KS; Horst, HA; Krauter, J; Girschikofsky, M; Ringhoffer, M; Südhoff, T; Held, G; Derigs, HG; Schroers, R; Greil, R; Grießhammer, M; Lange, E; Burchardt, A; Martens, U; Hertenstein, B; Marretta, L; Heuser, M; Thol, F; Gaidzik, VI; Herr, W; Krzykalla, J; Benner, A; Döhner, K; Ganser, A; Paschka, P; Döhner, H; Blood. 2019; 133(8):840-851

Hunting Poses Only a Low Risk for Alveolar Echinococcosis

Wetscher, M; Hacklander, K; Faber, V; Taylor, N; Auer, H; Duscher, GG FRONT PUBLIC HEALTH. 2019; 7: 7

Immunosuppressives and biologics during pregnancy and lactation: Aconsensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation

Puchner, A; Groochenig, HP; Sautner, J; Helmy-Bader, Y; Juch, H; Reinisch, S; Hogenauer, C; Koch, R; Hermann, J; Studnicka-Benke, A; Weger, W; Puchner, R; Dejaco, C WIEN KLIN WOCHENSCHR. 2019; 131(1-2): 29-44.

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Spicka, I; Ocio, EM; Oakervee, HE; Greil, R; Banh, RH; Huang, SY; DxxxRozario, JM; Dimopoulos, MA; Martinez, S; Extremera, S; Kahatt, C; Alfaro, V; Carella, AM; Meuleman, N; Hajek, R; Symeonidis, A; Min, CK; Cannell, P; Ludwig, H; Sonneveld, P; Mateos, MV ANN HEMATOL. 2019; 98(9): 2139-2150.

TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma

Hammel, P; Berardi, R; Creemers, G; Van Cutsem, E; Cubillo, A; Greil, R; Wasan, H; Metges, J; Noel, M; Nygren, P; Osterlund, P; Seufferlein, T; Macarulla, T; Fountzilas, C; Gupta, A; Grummer, L; Kacel, S; Biswas-Baldwin, N; Kay, R; Youssoufian, H; El-Hariry, I; Hidalgo, M ANN ONCOL. 2020; 31: S115-S115.

A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer

Lordick, F; Orra, EB; Cervantes, A; Dayyani, F; Rocha-Lima, C; Greil, R; van Laarhoven, H; Lorenzen, S; Kischel, R; Shitara, K; Chao, J ANN ONCOL. 2020; 31: S114-S114.

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Tran, B; Horvath, L; Dorff, TB; Greil, R; Machiels, JPH; Roncolato, F; Autio, KA; Rettig, M; Fizazi, K; Lolkema, MP; Fermin, AC; Salvati, M; Kouros-Mehr, H J CLIN ONCOL. 2020; 38(6):

TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

Hammel, P; Berardi, R; Van Cutsem, E; Feliu, J; Greil, R; Wasan, HS; Metges, JP; Nygren, P; Osterlund, PJ; Noel, MS; Seufferlein, T; Creemers, GY; Gupta, A; Salesse, S; Biswas-Baldwin, N; Dion, H; Youssoufian, H; Garzon, FT; El-Hariry, I; Hidalgo, M J CLIN ONCOL. 2020; 38(4):